Friday, January 30, 2026

What is the Visas for? How New US-Korea Agreement Eases Work for Korean Companies

U.S. and South Korea address visa issues for business activities post-detention incident, easing industry concerns but uncertainties remain.

North Korea’s Anti-U.S. Rheteorics Grows ahead of U.S. Presidential Election

Kim has labeled the U.S. a "hostile state" that they will contend with for generations ahead of the upcoming U.S. election in November.

North Korea’s Cyber Army Rises: Seoul Expert Warns of ‘Software Killers’ and AI-Driven Espionage

North Korea's cyber threats are evolving, targeting key sectors in South Korea and posing significant risks to national security.

Do Min Jang

Author's Latest

2025’s Drug Price Revolution: What Asian Pharma Firms Need to Know About MFN Policies

Trump's second term sees U.S. drug pricing reforms and supply chain shifts, prompting South Korean firms to seize new opportunities.

Patches, Implants, and Oral Films… The Drug-Delivery Format Battle After Oral Wegovy

Oral Wegovy's launch is transforming obesity treatment, focusing on user-friendly delivery methods and enhancing patient adherence.

Celltrion’s Eydenzelt: How Strategic Patent Agreements Enable U.S. and European Market Entry in 2026

Celltrion's Eydenzelt secures global distribution via strategic patent agreements, aiming for swift market entry in the U.S. and Europe.

TRUST ME, I’m an Expert: Trump’s Tylenol-Autism Claim Exposes Washington’s Dangerous NEW Brand of Idiocy

Trump claims Tylenol during pregnancy may raise autism risk, but medical experts refute this as unsupported by scientific evidence.

Fever’s Bigger Risk: Why the Tylenol Controversy Puts Moms in a Bind

Controversy surrounds acetaminophen use during pregnancy and its alleged link to autism, but evidence remains inconclusive.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Bio-Revolution: Celltrion’s $700M Biosimilar Is Reshaping the Global Drug Market

Celltrion's breakthrough in antibody biosimilars is transforming healthcare, enhancing access and innovation in treatment options.

Sales and Trust: How Celltrion is Revolutionizing the European Market Directly Connected

Celltrion leverages direct sales in Europe to enhance trust and supply stability while introducing biosimilars like Omlyclo for asthma treatment.

Celltrion’s Biosimilar Success in Europe Paves the Way for a US Market Takeover

Celltrion's booth at EADV 2025 highlighted biosimilar innovations, showcasing promising clinical trial results and expanding treatment access.

Biosimilars No Longer Second-Best: Highlighting Cost Savings and Improved Patient Access

Biosimilars are becoming standard care, with growing confidence in their safety and efficacy, driven by cost savings and improved accessibility.

Saving Poverty vs Free Trade Society? How Celltrion’s Biosimilar Could Reshape the U.S. Healthcare Market

Professor Metz highlights biosimilars' potential to expand patient access to treatments, emphasizing Omliclo's impact at EADV conference.

As Wegovy and Mounjaro Soar, Korean Biotechs Seek a Slice of the Obesity Drug Market

South Korean firms are innovating in the GLP-1 obesity treatment market, developing unique drugs to compete with industry leaders.

This New Drug Could Stop Kidney Failure After Heart Surgery

Bilix receives MFDS approval for Phase 2a trial of Brixelle, targeting acute kidney injury in cardiac surgery patients.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.